Atelerix, a Cambridge and Newcastle, UK - based spin - out from the University of Newcastle and creators of an innovative
cell encapsulation technology, closed a round of funding of undisclosed amount.
«When we discovered that CMA was thermoreversible, we thought CMA may have some interesting applications
in cell encapsulation and harvesting.
This crosslinking mechanism has been used to produce tissue sealants from polymers that are commonly used in tissue engineering studies — fibrinogen and gelatin (Elvin et al. 2011; Elvin et al. 2010), but so far, there have been relatively few studies using Ruthenium - mediated crosslinking
for cell encapsulation.
Their crew has exclusive real - time access to a top lab conducting the first
human cell encapsulation research trial of its kind.
«Because of this, the hydrogels may have numerous biomedical research uses and medical device application, including use as scaffolds or artificial extracellular matrix for tissue engineering and healing wounds; cell therapies; combining with stem cells to repair or replace organs; drug delivery; an adjuvant for vaccines; and drug and
cell encapsulation.»
Novocell has three primary technologies: stem cell engineering,
cell encapsulation and drug discovery.
These developments widen the field of research and biomedical applications of
the cell encapsulation technology.